P-P29 The glycated haemoglobin (HbA1c) test is not a predictor of pancreatectomy specific complications or survival

Abstract Background The glycated haemoglobin (HbA1c) test is a venous blood used as diagnostic for diabetes mellitus and to monitor glucose control in patients known have diabetes. has been recommended by National Institute Health Care Excellence (NICE) clinical guidelines the pre-operative setting since 2016. purpose of testing reduce perioperative morbidity mortality optimising management levels period. aim this study was assess prognostic value HbA1c pancreatic cancer treated with pancreaticoduodenectomy. Methods This retrospective analysis prospectively managed database resections at single institution from January 2016 December 2020. Included had confirmed adenocarcinoma underwent pancreaticoduodenectomy preoperative measurement their HbA1c. Patients who were already prescribed insulin excluded. Demographic data, survival, operative details collected. patient records assessed incidence postoperative complications accordance International Study Group Pancreatic Surgery fistula, delayed gastric emptying post pancreatectomy haemorrhage. An greater than 41 deemed elevated. Results There 145 met inclusion criteria. level normal 101/145 (70%) elevated 44/45 (30%). fistula rate 18% 23% those (p = 0.499). 21 respectively. five relaparotomies overall, one these an no deaths. Overall survival 31months (95%CI 27-35) HbAlc 32months 27-38) if Conclusions little doubt that helpful package assessment tests optimise surgery. However, planned not predictive specific such emptying, relaparotomy or mortality. In addition, long-term overall influenced HbAlc.